<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916720</url>
  </required_header>
  <id_info>
    <org_study_id>480848/010</org_study_id>
    <nct_id>NCT01916720</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy</brief_title>
  <official_title>A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of the Lp-PLA2 Inhibitor SB-480848 (40, 80mg od) on Carotid Plaque Composition in Patients With Carotid Artery Disease and Planned Carotid Endarterectomy, Stratified for Statin Use and Gender, After 14+/-4 Days Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine Lp-PLA2 activity in atherosclerotic carotid plaques
      after 14 (+/-4) days treatment with darapladib, compared to placebo. Secondary objectives
      include determination of the change in Lp-PLA2 activity in blood, Lp-PLA2 mass in blood and
      plaque, specified biomarkers in blood and plaque and their respective correlation's with
      Lp-PLA2. In addition, the study aims to characterise the PK/PD of repeat oral doses of
      SB-480848, and safety and tolerability in this population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lp-PLA2 activity in the atherosclerotic plaque removed during carotid endarterectomy</measure>
    <time_frame>14 +/- 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lp-PLA2 mass in plaque removed during the carotid endarterectomy</measure>
    <time_frame>14 +/- 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lp-PLA2 mass and activity in blood</measure>
    <time_frame>14 +/- days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid and Non-Lipid Biomarkers in Plasma</measure>
    <time_frame>14 +/- days</time_frame>
    <description>Lipids: total cholesterol, HDL, LDL, and triglycerides Non-Lipids: hsCRP, CD40L, ICAM-1, E-selectin, PAI-1 antibody, PAI-1 antigen, and MMP-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidised Lipids and Their Metabolites, and Biomarkers in Plaque</measure>
    <time_frame>14 +/- 4 days</time_frame>
    <description>Oxidised Lipids and Their Metabolites: total lyso-PC, total phospholipid, and total phosphatidylcholine Biomarkers: CD68 (macrophages), CD3 (T cells), CD20 or CD22 (B cells), alpha-actin (smooth muscle cells), CD40L, MMP-2, MMP-9, PAI-1, ICAM-1, IL-6, and Lp-PLA2 (mRNA expression)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>SB-480848 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB-480848 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-480848 40 mg</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>SB-480848 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-480848 80 mg</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>SB-480848 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>SB-480848 40 mg</arm_group_label>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, &gt;35 years of age

          -  Females of childbearing potential must be using approved contraceptive measures

          -  Male patients must be willing to abstain from sexual intercourse or use a form of
             contraception if engaging in sexual intercourse with a woman who could become pregnant

          -  Planned carotid endarterectomy within a timeframe compatible with recruitment for the
             study and able to comply with the requirements of the study, as deemed by the
             investigator

          -  Written, informed consent to participate

        Exclusion Criteria:

          -  Recent myocardial infarction (within the previous 4 weeks)

          -  Currently taking corticosteroids, warfarin, digoxin or a potent CYP3A4 inhibitor

          -  Recent (&lt;3 months) or ongoing acute infection or significant trauma associated with
             bruising and/or taking antibiotics. Prophylactic antibiotics for surgery are allowed

          -  Change in dose of lipid-lowering therapy during the previous 4 weeks from
             randomisation

          -  History of chronic liver disease (e.g. cirrhosis, hepatitis) OR ALT OR AST â‰¥1.5 times
             the upper limit of normal (ULN) at screening

          -  Diagnosis of systemic lupus erythematosis (SLE) or rheumatoid arthritis (RA)

          -  Clinically significant anaemia

          -  History of severe renal impairment (serum creatinine &gt;1.8mg/dL)

          -  Unstable angina

          -  History of asthma , anaphylaxis or anaphylactoid reactions, severe allergic responses

          -  Abuse of alcohol or drugs within the last 6 months

          -  Any factor or clinical disease state that, in the investigator's opinion, would
             preclude completion of a safe surgical procedure and/or completion of the study

          -  Use of an investigational drugs within 30 days or 5 half-lives of their last dose
             prior to starting the study, whichever is the longest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>480848/010</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/010</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/010</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/010</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/010</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/010</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/010</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

